STAAR Surgical traded at $75.68 this Wednesday July 6th, decreasing $0.50 or 0.66 percent since the previous trading session. Looking back, over the last four weeks, STAAR Surgical lost 9.29 percent. Over the last 12 months, its price fell by 48.04 percent. Looking ahead, we forecast STAAR Surgical to be priced at 70.23 by the end of this quarter and at 64.68 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 108.69 -0.61 -0.56% -9.33%
Atrion 619.40 -8.80 -1.40% 4.02%
Boston Scientific 37.66 -0.10 -0.26% -14.27%
Cerus 5.60 -0.14 -2.44% 7.49%
Cooper Companies 312.60 -3.29 -1.04% -24.46%
Exact Sciences 43.29 -1.11 -2.50% -63.23%
Hologic 70.88 0.69 0.98% 1.78%
J&J 178.30 0.16 0.09% 5.25%
Merit Medical Systems 53.36 -1.10 -2.02% -16.03%
Novartis 81.22 0.31 0.38% -4.41%
Orthofix International 24.14 -0.26 -1.07% -38.18%
OraSure Technologies 2.77 -0.01 -0.36% -72.76%
Rockwell Medical 1.29 -0.01 -0.77% 62.28%
Sientra 0.85 -0.03 -3.34% -89.25%
STAAR Surgical 75.68 -0.50 -0.66% -48.04%
Utah Medical Products 84.37 -0.11 -0.13% -1.86%
Meridian Bioscience 33.55 2.20 7.02% 52.36%
Bausch Health Companies Inc 11.16 -0.64 -5.42% -69.24%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US2000 1728 -13.78 -0.79% -23.32%

STAAR Surgical
STAAR Surgical Company is a developer, producer, and marketer of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company's principal products are implantable Collamer lenses (ICLs) and intraocular lenses (IOLs). ICLs, consists of the Company’s ICL family of products, including the Toric implantable Collamer lenses (TICL) and EVO+ Visian ICL, are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness), hyperopia (far-sightedness), astigmatism, and presbyopia. IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts, and include the Company’s lines of silicone IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). The Company sells its products in more than 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore.